Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 471Neoplasms 328Colorectal Neoplasms 235Carcinoma, Non-Small-Cell Lung 234Lung Neoplasms 200Prostatic Neoplasms 179Carcinoma, Hepatocellular 174Stomach Neoplasms 138Pancreatic Neoplasms 126Leukemia, Myeloid, Acute 114Uterine Cervical Neoplasms 110Rectal Neoplasms 105Multiple Myeloma 94Recurrence 89Squamous Cell Carcinoma of Head and Neck 84Head and Neck Neoplasms 79Neoplasm Metastasis 76Ovarian Neoplasms 75Brain Neoplasms 71Colonic Neoplasms 68Glioblastoma 67Esophageal Neoplasms 66Triple Negative Breast Neoplasms 65Endometrial Neoplasms 58Precursor Cell Lymphoblastic Leukemia-Lymphoma 56Small Cell Lung Carcinoma 54Disease 54Motor Activity 53Hematologic Neoplasms 53Glioma 48

Interventions

irinotecan sucrosofate 1Tegafur 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × OTHER × Efficacy and Safety × Clear all
NCT06383078 2024-04-25

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
120 enrolled

Efficacy and Safety

Data powered by HemOnc (CC BY 4.0) Colophon âš¡